Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models

Abstract Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced gastrointestinal stromal tumors or treatment‐refrac...

Full description

Bibliographic Details
Main Authors: Dieter Zopf, Iduna Fichtner, Ajay Bhargava, Wolfram Steinke, Karl‐Heinz Thierauch, Konstanze Diefenbach, Scott Wilhelm, Frank‐Thorsten Hafner, Michael Gerisch
Format: Article
Language:English
Published: Wiley 2016-11-01
Series:Cancer Medicine
Subjects:
Antitumor activity
metabolite
multikinase inhibitor
pharmacology
regorafenib
Online Access:https://doi.org/10.1002/cam4.883

Internet

https://doi.org/10.1002/cam4.883

Similar Items